Clinical Outcomes and Lack of Health Equity in Minority Patients with Unresectable Non-small Cell Lung Cancer (NSCLC) Treated with Durvalumab

被引：0
|
作者：
Fares, A. [1 ]
Theik, N. [2 ]
Dumais, K. [3 ]
Walker, D. [3 ]
Rodriguez, M. [1 ]
Dickson, F. [4 ]
Swaby, G. [5 ]
Alvarez, A. M. [3 ]
Raez, L. E. [3 ]
机构：
[1] Mem Canc Inst, Pembroke Pines, FL USA
[2] Mem Healthcare Syst, Pembroke Pines, FL USA
[3] Florida Atlantic Univ FAU, Mem Canc Inst, Pembroke Pines, FL USA
[4] BMS, Pembroke Pines, FL USA
[5] Mem Healthcare Syst, Pembroke Pines, GA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
Disparities; NSCLC; Immunotherapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP17.04-06
引用
收藏
页码：S741 / S741
页数：1
相关论文
共 50 条
  • [31] Influence of durvalumab consolidation on pneumonitis after chemoradiotherapy for unresectable non-small cell lung cancer
    Murata, Saori
    Horinouchi, Hidehito
    Morishita, Momoko
    Kaku, Sawako
    Shinno, Yuki
    Okuma, Yusuke
    Yoshida, Tatsuya
    Goto, Yasushi
    Yamamoto, Noboru
    Okuma, Kae
    Kusumoto, Masahiko
    Ohe, Yuichiro
    ANNALS OF ONCOLOGY, 2023, 34 : S1396 - S1396
  • [32] Durvalumab for the treatment of non-small cell lung cancer
    Mezquita, Laura
    Planchard, David
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2018, 12 (08) : 627 - 639
  • [33] Durvalumab for the treatment of non-small cell lung cancer
    Murakami, Shuji
    EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (12) : 1009 - 1016
  • [34] Immunotherapy in previously treated non-small cell lung cancer (NSCLC)
    Leal, Ticiana A.
    Ramalingam, Suresh S.
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S422 - S432
  • [35] A study of the efficacy and toxicity outcomes of extended durvalumab dosing in patients with stage III unresectable non-small cell lung cancer (NSCLC) during the COVID-19 pandemic
    Hanna, Lilian
    Moffat, Gordon Taylor
    Hopman, Wilma
    Gaudreau, Pierre-Olivier
    Fung, Andrea S.
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2023, 34
  • [36] EXPLORING DISPARITIES IN HEALTH CARE OUTCOMES IN MINORITY POPULATIONS WITH SMALL (SCLC) AND NON-SMALL CELL LUNG CANCERS (NSCLC)
    Raez, Luis E.
    Sareli, Candice
    Mudad, Raja
    Tarrazzi, Francisco
    Velis, Evelio
    Sundararaman, Srinath
    Block, Mark
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S325 - S325
  • [37] ADHERENCE AND ITS ASSOCIATION WITH HEALTH OUTCOMES AMONG PATIENTS CURRENTLY TREATED FOR LEUKEMIA, MELANOMA, OR NON-SMALL CELL LUNG CANCER (NSCLC)
    Goren, A.
    DiBonaventura, M.
    Wagner, R.
    VALUE IN HEALTH, 2013, 16 (03) : A144 - A145
  • [38] Observational study of patients with non-small cell lung cancer (NSCLC) treated by erlotinib: Clinical practices and main outcomes in France (OBSTAR).
    Vergnenegre, A.
    Monnet, I.
    Chouaid, C.
    Hureaux, J.
    Mazieres, J.
    Quere, G.
    Lombard, J.
    Cumin, I.
    Abdiche, S.
    Decroisette, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [39] Outcomes of Nivolumab in Elderly Patients (pts) with Non-Small Cell Lung Cancer (NSCLC)
    Bagley, Stephen
    Kothari, Shawn
    Aggarwal, Charu
    Bauml, Joshua
    Alley, Evan
    Evans, Tracey
    Kosteva, John
    Ciunci, Christine
    Thompson, Jeffrey
    Stonehouse-Lee, Susan
    Sherry, Victoria
    Gilbert, Elizabeth
    Eaby-Sandy, Beth
    Mutale, Faith
    Dilullo, Gloria
    Cohen, Roger
    Vachani, Anil
    Langer, Corey
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1289 - S1289
  • [40] NRAS mutated non-small cell lung cancer (NSCLC) patients: Characteristics and outcomes
    Dehem, A.
    Mazieres, J.
    Chour, A.
    Guisier, F.
    Ferreira, M.
    Boussageon, M.
    Girard, N.
    Moro-Sibilot, D.
    Cadranel, J.
    Zalcman, G.
    Ricordel, C.
    Wislez, M.
    Munck, C.
    Poulet, C-H.
    Gauvain, C.
    Descarpentries, C.
    Wasielewski, E.
    Cortot, A. B.
    Baldacci, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S1023 - S1024
12345